Lab webpage: Prostate Cancer Research Group

Google Scholar: https://scholar.google.com.au/citations?user=IfXWSaQAAAAJ&hl=en

ORCID: https://orcid.org/0000-0002-4686-1418

Professor Luke Selth is Head of the Prostate Cancer Research within the Flinders Health and Medical Research Institute (FHMRI), Co-Director of FHMRI's Cancer Impact program, and a Cancer Council SA Beat Cancer Principal Research Fellow (2020-2025).

Selth has established an internationally-recognised research program focused on understanding and targeting androgen receptor signalling in prostate cancer, investigating prostate cancer cell plasticity and how it leads to therapy resistance, and testing the efficacy of novel drugs for prostate cancer.

Selth did a Biotechnology degree at Flinders University, a PhD at University of Adelaide and then post-doctoral studies at Cancer Research UK’s London Research Institute. As a recipient of a prestigious European Molecular Biology Organization long-term fellowship, Selth studied epigenetic mechanisms underlying transcriptional deregulation in cancer and developed expertise in contemporary molecular, biochemical and omic techniques. Since returning to Australia, Selth’s research has been focussed on prostate cancer, an extremely common disease and a major cause of cancer-related death in men.

Selth is a member of the Freemasons Centre for Male Health and Wellbeing and the Scientific Advisory Committee for the South Australian Genomics Centre. He has received Young Investigator Awards from the Prostate Cancer Foundation of Australia (PCFA) and the USA Prostate Cancer Foundation, the latter being the most prestigious award for early-career researchers establishing independent programs in the prostate cancer field. He has received recent funding from National Health and Medical Research Council, Cancer Australia, Cancer Council SA, Cancer Council NSW, the Flinders Foundation, Movember and The Hospital Research Foundation. He is on the Editorial Boards of Endocrine-Related Cancer, the flagship cancer journal for the Society of Endocrinology, and Cancer Research Communications (American Association for Cancer Research). His team’s research is regularly published in prominent journals including recent papers in Cancer Research, European Urology, Science Translational Medicine, Nature Cell Biology, Nature Medicine, EMBO Journal, Oncogene, and Nucleic Acids Research.